Zobrazeno 91 - 100
of 155
pro vyhledávání: '"Marc Espié"'
Autor:
Anne Dumay, Jean-Paul Feugeas, Evelyne Wittmer, Jacqueline Lehmann-Che, Philippe Bertheau, Marc Espié, Louis-François Plassa, Paul Cottu, Michel Marty, Fabrice André, Christos Sotiriou, Lajos Pusztai, Hugues de Thé
Publikováno v:
International journal of cancer. 132(5)
Tumor protein p53 (TP53) is mutated in approximately 30% of breast cancers, but this frequency fluctuates widely between subclasses. We investigated the p53 mutation status in 572 breast tumors, classified into luminal, basal and molecular apocrine s
Autor:
Miguel Gil, Marc Espié, Frederico Costa, José Baselga, Bernardo Garicochea, Antonio Llombart, Brigitte M. Van Eyll, Begoña Bermejo, Josefa Morales, Sunhee Kwon Ro, Henri Roché, Hélio Pinczowski, J.G.M. Segalla, Patricia Gomez, Miguel Angel Climent Duran, Auro Del Giglio, Clarissa Mathias, Eva Ciruelos, Belén Ojeda, Paulo M. Hoff, Ronaldo A. Ribeiro, Shell Li, Sebastiao Cabral Filho, Andre Augusto Junior Gemeinder de Moraes
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Purpose Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth
Autor:
Fabien Calvo, J.M. Extra, A. de Rocquancourt, E. Bourstyn, G Linares, Marc Espié, P. de Cremoux, Annick Faille, Sylvie Giacchetti, Michel Marty
Publikováno v:
British Journal of Cancer
Alterations in the p53 gene were analysed in 39 patients with locally advanced breast cancers (LABCs) (stage III-IV) with inflammatory signs in most cases (UICC stage T4d = 32 patients) by molecular and immunohistochemical (IHC) approaches. All patie
Autor:
Laurent Mignot, Bernard Visot, Sylvie Giacchetti, Michel Marty, Paul Cottu, Jean Marc Extra, Marc Espié, Bernard Epardeau
Publikováno v:
Journal of Neuro-Oncology. 18:19-23
Medulloblastoma is a rare tumor in adult. High doses of megavoltage irradiation of the posterior fossa have been resulted in a better survival (48 to 78% at 5 years) of the patient. It is sensitive to a wide variety of chemotherapy drugs, but adjuvan
Publikováno v:
La Revue de Médecine Interne. 15:318-324
Resume Les metastases oculaires (MO) sont devenues moins rares depuis que les traitements systemiques de certains cancers permettent de prolonger la survie des patients. Les cancers les plus frequemment en cause sont les cancers du sein pour lesquels
Autor:
Robert E. Coleman, Lucy Kilburn, Nicole Tubiana-Mathieu, Andrew M Wardley, Judith M Bliss, M. Thomas, J. Wals, Pierre Hupperets, Michel Marty, R. Charles Coombes, Derek Cooper, Marinus O. den Boer, Marc Espié, Alejandro Tres, Katie Wilkinson, Frans L. G. Erdkamp, J. A. Reise
Publikováno v:
Journal of Clinical Oncology, 29(24), 3247-3254. American Society of Clinical Oncology
Purpose The Docetaxel Epirubicin Adjuvant (DEVA) trial evaluated the efficacy and toxicity of incorporating docetaxel after epirubicin to create a sequential anthracycline-taxane regimen in early breast cancer. Patients and Methods After complete tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcfc60d40d9ab7b636c279ed3c348a01
https://cris.maastrichtuniversity.nl/en/publications/d7147be1-2cb5-479d-b32b-e4f91ea81290
https://cris.maastrichtuniversity.nl/en/publications/d7147be1-2cb5-479d-b32b-e4f91ea81290
Autor:
Isabelle Brenot-Rossi, Marc Espié, Jean-Luc Moretti, Elif Hindié, Domenico Rubello, David Groheux
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 52(3)
Axillary node status is a major prognostic factor in early breast cancer. Staging with sentinel node biopsy (SNB) leads to a substantial reduction in surgical morbidity. Recent multiinstitutional studies revealed SNB false-negative rates ranging from
Autor:
Nathalie Berenger, Marie Elisabeth Toubert, Christophe Hennequin, Elif Hindié, Laetitia Vercellino, Paolo Zanotti-Fregonara, Jacques R. Vilcoq, David Groheux, Marc Espié, C. Maylin
Publikováno v:
International journal of radiation oncology, biology, physics. 83(4)
Given the risk of undesired toxicity, prophylactic internal mammary (IM) chain irradiation should be offered only to patients at high risk of occult involvement. Lymphoscintigraphy for axillary sentinel node biopsy might help in selecting these patie
Autor:
Marie-Christine Mathieu, Jean-Yves Pierga, Suzette Delaloge, Alexia Savignoni, Marc Espié, Marc Spielmann, Brigitte Sigal-Zafrani, P Bertheau, Etienne Brain, Jean Marc Guinebretière, Michel Marty
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2010, 122 (2), pp.429-437. ⟨10.1007/s10549-010-0939-3⟩
Breast Cancer Research and Treatment, Springer Verlag, 2010, 122 (2), pp.429-437. 〈10.1007/s10549-010-0939-3〉
Breast Cancer Research and Treatment, Springer Verlag, 2010, 122 (2), pp.429-437. ⟨10.1007/s10549-010-0939-3⟩
Breast Cancer Research and Treatment, Springer Verlag, 2010, 122 (2), pp.429-437. 〈10.1007/s10549-010-0939-3〉
International audience; To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addition of celecoxib in HER2 negative patients or trastuzumab in HER2 positive patients. From May 2004 till Oct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baee08a3b75c6f239f78395831171fe2
https://hal.archives-ouvertes.fr/hal-00537245
https://hal.archives-ouvertes.fr/hal-00537245
Autor:
Jacqueline Lehmann-Che, Fabrice André, Christine Desmedt, Chafika Mazouni, Sylvie Giacchetti, Elisabeth Turpin, Marc Espié, Louis-François Plassa, Michel Marty, Philippe Bertheau, Christos Sotiriou, Martine Piccart, W. Fraser Symmans, Lajos Pusztai, Hugues Thé
Publikováno v:
The oncologist. 15(3)
Learning Objectives After completing this course, the reader will be able to: Analyze the role of p53 mutation in ER-negative tumors in conferring increased sensitivity to high-dose alkylating agents, in order to treat patients with this phenotype us